Tarlatamab 1mg powder and solution for solution for infusion vials
Requires a prescription from a doctor or prescriber
Cytotoxic drugs
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Tarlatamab on the MHRA register
Imdylltra 1mg powder for concentrate and solution for solution for infusion vials
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Tarlatamab
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(2)
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (TA1091)
Lung cancer: diagnosis and management (NG122)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
11.2 days
Mechanism
Tarlatamab is a bispecific monoclonal antibody and T-cell engager.
Food interactions
None known
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
100%
[L50743]…
Half-life
11.2 days
[L50743]
Volume of distribution
[L50743]
Metabolism
[L50743]…
Clearance
0.65 L
[L50743]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Tarlatamab-dlle was approved by the FDA in May 2024 for use in patients who have failed previous round of platinum-based chemotherapy,[L50743][L50748] becoming the first DLL3-targeting bispecific T-cell engager to receive marketing approval.[A263808]
[L50743]
Known interactions with other medications. Always consult a healthcare professional.
Showing 38 of 38 interactions
Tarlatamab serves to recruit and direct T-cells towards tumor cells expressing DLL3, resulting in T-cell activation and the release of inflammatory cytokines ultimately causing lysis of DLL3-expressing cells.[L50743]
Serious neurologic toxicities have been reported with the use of tarlatamab, including immune effector cell-associated neurotoxicity syndrome (ICANS). There was no observed exposure-response relationship with regards to efficacy over the studied dose range, but there was an increased risk of neurologic toxicity (including ICANS) and neutropenia at higher exposure.[L50743] Tarlatamab may also cause cytokine release syndrome (CRS), most commonly following the first dose, which can be serious or life-threatening.[L50743] Patients should be monitored closely for signs and symptoms suggestive of CRS or neurologic toxicities.
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L50743]
Following the first step-up dose of 1 mg, the geometric mean Cavg was 102 ng/mL, the geometric mean Cmax was 285, and the geometric mean Ctrough was 47 ng/mL.
[L50743]
At steady-state, with the administration of 10 mg every 2 weeks, the geometric mean Cavg was 1040 ng/mL, the geometric mean Cmax was 3400, and the geometric mean Ctrough was 495 ng/mL.
[L50743]
[L50743]
[L50743]
[L50743]
[L50743]
Proteins and enzymes this drug interacts with in the body
Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine kinases LCK and FYN, resulting in the activation of downstream signaling pathways .
PMID:1384049 PMID:1385158 PMID:2470098 PMID:7509083
CD3Z ITAMs phosphorylation creates multiple docking sites for the protein kinase ZAP70 leading to ZAP70 phosphorylation and its conversion into a catalytically active enzyme .
PMID:7509083
Plays an important role in intrathymic T-cell differentiation. Additionally, participates in the activity-dependent synapse formation of retinal ganglion cells (RGCs) in both the retina and dorsal lateral geniculate nucleus (dLGN) (By similarity)
ATC L01FX33
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Tarlatamab
Additional database identifiers
Drugs Product Database (DPD)
24006
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2909
GeneCards
DLL3
UniProt Accession
DLL3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1673
GenAtlas
CD3D
GeneCards
CD3D
GenBank Gene Database
X01451
UniProt Accession
CD3D_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1674
GenAtlas
CD3E
GeneCards
CD3E
GenBank Gene Database
X03884
GenBank Protein Database
469945
Guide to Pharmacology
2742
UniProt Accession
CD3E_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1675
GenAtlas
CD3G
GeneCards
CD3G
GenBank Gene Database
BC113830
UniProt Accession
CD3G_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1677
GenAtlas
CD247
GeneCards
CD247
GenBank Gene Database
BC025703
UniProt Accession
CD3Z_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: